{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:08:36Z","timestamp":1791918516941,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R00NS082379"],"award-info":[{"award-number":["R00NS082379"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS100947"],"award-info":[{"award-number":["R01NS100947"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS109687"],"award-info":[{"award-number":["R21NS109687"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12035-020-01923-4","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T12:03:40Z","timestamp":1588766620000},"page":"2830-2845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics"],"prefix":"10.1007","volume":"57","author":[{"given":"Ying","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suni M.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-8928","authenticated-orcid":false,"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"1923_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH (2015) A definition and classification of status epilepticus--report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56:1515\u20131523. https:\/\/doi.org\/10.1111\/epi.13121","journal-title":"Epilepsia"},{"key":"1923_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","volume":"14","author":"JP Betjemann","year":"2015","unstructured":"Betjemann JP, Lowenstein DH (2015) Status epilepticus in adults. Lancet Neurol 14:615\u2013624. https:\/\/doi.org\/10.1016\/S1474-4422(15)00042-3","journal-title":"Lancet Neurol"},{"key":"1923_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S1474-4422(11)70187-9","volume":"10","author":"AO Rossetti","year":"2011","unstructured":"Rossetti AO, Lowenstein DH (2011) Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 10:922\u2013930. https:\/\/doi.org\/10.1016\/S1474-4422(11)70187-9","journal-title":"Lancet Neurol"},{"key":"1923_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJM198702263160901","volume":"316","author":"JF Annegers","year":"1987","unstructured":"Annegers JF, Hauser WA, Shirts SB, Kurland LT (1987) Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med 316:493\u2013498. https:\/\/doi.org\/10.1056\/NEJM198702263160901","journal-title":"N Engl J Med"},{"key":"1923_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/qjmed\/hcn149","volume":"102","author":"MH Tsai","year":"2009","unstructured":"Tsai MH, Chuang YC, Chang HW, Chang WN, Lai SL, Huang CR, Tsai NW, Wang HC et al (2009) Factors predictive of outcome in patients with de novo status epilepticus. Qjm 102:57\u201362. https:\/\/doi.org\/10.1093\/qjmed\/hcn149","journal-title":"Qjm"},{"key":"1923_CR6","doi-asserted-by":"publisher","first-page":"18284","DOI":"10.3390\/ijms140918284","volume":"14","author":"DS Reddy","year":"2013","unstructured":"Reddy DS, Kuruba R (2013) Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int J Mol Sci 14:18284\u201318318. https:\/\/doi.org\/10.3390\/ijms140918284","journal-title":"Int J Mol Sci"},{"key":"1923_CR7","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","volume":"42","author":"W Loscher","year":"2017","unstructured":"Loscher W (2017) Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res 42:1873\u20131888. https:\/\/doi.org\/10.1007\/s11064-017-2222-z","journal-title":"Neurochem Res"},{"key":"1923_CR8","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1212\/WNL.0000000000001673","volume":"84","author":"I Sanchez Fernandez","year":"2015","unstructured":"Sanchez Fernandez I, Abend NS, Agadi S, An S, Arya R, Brenton JN, Carpenter JL, Chapman KE et al (2015) Time from convulsive status epilepticus onset to anticonvulsant administration in children. Neurology 84:2304\u20132311. https:\/\/doi.org\/10.1212\/WNL.0000000000001673","journal-title":"Neurology"},{"key":"1923_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/acem.13811","volume":"26","author":"AG Sathe","year":"2019","unstructured":"Sathe AG, Tillman H, Coles LD, Elm JJ, Silbergleit R, Chamberlain J, Kapur J, Cock HR et al (2019) Underdosing of benzodiazepines in patients with status epilepticus enrolled in established status epilepticus treatment trial. Acad Emerg Med 26:940\u2013943. https:\/\/doi.org\/10.1111\/acem.13811","journal-title":"Acad Emerg Med"},{"key":"1923_CR10","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","volume":"75","author":"E Trinka","year":"2015","unstructured":"Trinka E, Hofler J, Leitinger M, Brigo F (2015) Pharmacotherapy for status epilepticus. Drugs 75:1499\u20131521. https:\/\/doi.org\/10.1007\/s40265-015-0454-2","journal-title":"Drugs"},{"key":"1923_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-pharmtox-010814-124607","volume":"55","author":"NH Varvel","year":"2015","unstructured":"Varvel NH, Jiang J, Dingledine R (2015) Candidate drug targets for prevention or modification of epilepsy. Annu Rev Pharmacol Toxicol 55:229\u2013247. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124607","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1923_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fneur.2019.00427","volume":"10","author":"L Horvath","year":"2019","unstructured":"Horvath L, Fekete I, Molnar M, Valoczy R, Marton S, Fekete K (2019) The outcome of status epilepticus and long-term follow-up. Front Neurol 10:427. https:\/\/doi.org\/10.3389\/fneur.2019.00427","journal-title":"Front Neurol"},{"key":"1923_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","volume":"7","author":"A Vezzani","year":"2011","unstructured":"Vezzani A, French J, Bartfai T, Baram TZ (2011) The role of inflammation in epilepsy. Nat Rev Neurol 7:31\u201340. https:\/\/doi.org\/10.1038\/nrneurol.2010.178","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 3","key":"1923_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/epi.13783","volume":"58","author":"E Aronica","year":"2017","unstructured":"Aronica E, Bauer S, Bozzi Y, Caleo M, Dingledine R, Gorter JA, Henshall DC, Kaufer D et al (2017) Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia 58(Suppl 3):27\u201338. https:\/\/doi.org\/10.1111\/epi.13783","journal-title":"Epilepsia"},{"key":"1923_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/epi.13965","volume":"59","author":"P Klein","year":"2018","unstructured":"Klein P, Dingledine R, Aronica E, Bernard C, Blumcke I, Boison D, Brodie MJ, Brooks-Kayal AR et al (2018) Commonalities in epileptogenic processes from different acute brain insults: do they translate? Epilepsia 59:37\u201366. https:\/\/doi.org\/10.1111\/epi.13965","journal-title":"Epilepsia"},{"key":"1923_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tips.2016.03.001","volume":"37","author":"A Dey","year":"2016","unstructured":"Dey A, Kang X, Qiu J, Du Y, Jiang J (2016) Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside. Trends Pharmacol Sci 37:463\u2013484. https:\/\/doi.org\/10.1016\/j.tips.2016.03.001","journal-title":"Trends Pharmacol Sci"},{"key":"1923_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2017.10.012","volume":"109","author":"ND Schartz","year":"2018","unstructured":"Schartz ND, Wyatt-Johnson SK, Price LR, Colin SA, Brewster AL (2018) Status epilepticus triggers long-lasting activation of complement C1q-C3 signaling in the hippocampus that correlates with seizure frequency in experimental epilepsy. Neurobiol Dis 109:163\u2013173. https:\/\/doi.org\/10.1016\/j.nbd.2017.10.012","journal-title":"Neurobiol Dis"},{"key":"1923_CR18","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.pharmthera.2020.107504","volume":"209","author":"Marwa M. Nagib","year":"2020","unstructured":"Nagib MM, Yu Y, Jiang J (2020) Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Pharmacol Ther:107504. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107504","journal-title":"Pharmacology & Therapeutics"},{"key":"1923_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrd4126","volume":"12","author":"W Loscher","year":"2013","unstructured":"Loscher W, Klitgaard H, Twyman RE, Schmidt D (2013) New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 12:757\u2013776. https:\/\/doi.org\/10.1038\/nrd4126","journal-title":"Nat Rev Drug Discov"},{"key":"1923_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuropharm.2012.04.004","volume":"69","author":"A Vezzani","year":"2013","unstructured":"Vezzani A, Friedman A, Dingledine RJ (2013) The role of inflammation in epileptogenesis. Neuropharmacology 69:16\u201324. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.04.004","journal-title":"Neuropharmacology"},{"key":"1923_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nrn3937","volume":"16","author":"I Soltesz","year":"2015","unstructured":"Soltesz I, Alger BE, Kano M, Lee SH, Lovinger DM, Ohno-Shosaku T, Watanabe M (2015) Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. Nat Rev Neurosci 16:264\u2013277. https:\/\/doi.org\/10.1038\/nrn3937","journal-title":"Nat Rev Neurosci"},{"key":"1923_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/glia.20983","volume":"58","author":"N Stella","year":"2010","unstructured":"Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017\u20131030. https:\/\/doi.org\/10.1002\/glia.20983","journal-title":"Glia"},{"key":"1923_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneumeth.2013.03.021","volume":"216","author":"JH Baek","year":"2013","unstructured":"Baek JH, Darlington CL, Smith PF, Ashton JC (2013) Antibody testing for brain immunohistochemistry: brain immunolabeling for the cannabinoid CB(2) receptor. J Neurosci Methods 216:87\u201395. https:\/\/doi.org\/10.1016\/j.jneumeth.2013.03.021","journal-title":"J Neurosci Methods"},{"key":"1923_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1124\/mol.114.094649","volume":"86","author":"A Dhopeshwarkar","year":"2014","unstructured":"Dhopeshwarkar A, Mackie K (2014) CB2 cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol 86:430\u2013437. https:\/\/doi.org\/10.1124\/mol.114.094649","journal-title":"Mol Pharmacol"},{"key":"1923_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fnins.2016.00449","volume":"10","author":"W Bu","year":"2016","unstructured":"Bu W, Ren H, Deng Y, Del Mar N, Guley NM, Moore BM, Honig MG, Reiner A (2016) Mild traumatic brain injury produces neuron loss that can be rescued by modulating microglial activation using a CB2 receptor inverse agonist. Front Neurosci 10:449. https:\/\/doi.org\/10.3389\/fnins.2016.00449","journal-title":"Front Neurosci"},{"key":"1923_CR26","doi-asserted-by":"publisher","first-page":"101682","DOI":"10.1016\/j.pneurobio.2019.101682","volume":"183","author":"Y Yu","year":"2019","unstructured":"Yu Y, Nguyen DT, Jiang J (2019) G protein-coupled receptors in acquired epilepsy: druggability and translatability. Prog Neurobiol 183:101682. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.101682","journal-title":"Prog Neurobiol"},{"key":"1923_CR27","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1007\/s12035-017-0689-x","volume":"55","author":"J Zhang","year":"2018","unstructured":"Zhang J, Chen C (2018) Alleviation of neuropathology by inhibition of monoacylglycerol lipase in APP transgenic mice lacking CB2 receptors. Mol Neurobiol 55:4802\u20134810. https:\/\/doi.org\/10.1007\/s12035-017-0689-x","journal-title":"Mol Neurobiol"},{"key":"1923_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pharmthera.2016.06.011","volume":"166","author":"M Mecha","year":"2016","unstructured":"Mecha M, Carrillo-Salinas FJ, Feliu A, Mestre L, Guaza C (2016) Microglia activation states and cannabinoid system: therapeutic implications. Pharmacol Ther 166:40\u201355. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.06.011","journal-title":"Pharmacol Ther"},{"key":"1923_CR29","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/epi.13842","volume":"58","author":"MN Huizenga","year":"2017","unstructured":"Huizenga MN, Wicker E, Beck VC, Forcelli PA (2017) Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats. Epilepsia 58:1593\u20131602. https:\/\/doi.org\/10.1111\/epi.13842","journal-title":"Epilepsia"},{"key":"1923_CR30","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1111\/epi.13930","volume":"58","author":"S Rowley","year":"2017","unstructured":"Rowley S, Sun X, Lima IV, Tavenier A, de Oliveira ACP, Dey SK, Danzer SC (2017) Cannabinoid receptor 1\/2 double-knockout mice develop epilepsy. Epilepsia 58:e162\u2013e166. https:\/\/doi.org\/10.1111\/epi.13930","journal-title":"Epilepsia"},{"key":"1923_CR31","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/epi.16388","volume":"60","author":"L Shapiro","year":"2019","unstructured":"Shapiro L, Wong JC, Escayg A (2019) Reduced cannabinoid 2 receptor activity increases susceptibility to induced seizures in mice. Epilepsia 60:2359\u20132369. https:\/\/doi.org\/10.1111\/epi.16388","journal-title":"Epilepsia"},{"key":"1923_CR32","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.bmc.2015.07.057","volume":"23","author":"CS Presley","year":"2015","unstructured":"Presley CS, Mustafa SM, Abidi AH, Moore BM 2nd (2015) Synthesis and biological evaluation of (3\u2032,5\u2032-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl\/alkyl-methanone selective CB2 inverse agonist. Bioorg Med Chem 23:5390\u20135401. https:\/\/doi.org\/10.1016\/j.bmc.2015.07.057","journal-title":"Bioorg Med Chem"},{"key":"1923_CR33","doi-asserted-by":"publisher","first-page":"9293","DOI":"10.1074\/jbc.M113.455816","volume":"288","author":"Y Quan","year":"2013","unstructured":"Quan Y, Jiang J, Dingledine R (2013) EP2 receptor signaling pathways regulate classical activation of microglia. J Biol Chem 288:9293\u20139302. https:\/\/doi.org\/10.1074\/jbc.M113.455816","journal-title":"J Biol Chem"},{"key":"1923_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/mol.115.098202","volume":"88","author":"Y Fu","year":"2015","unstructured":"Fu Y, Yang MS, Jiang J, Ganesh T, Joe E, Dingledine R (2015) EP2 receptor signaling regulates microglia death. Mol Pharmacol 88:161\u2013170. https:\/\/doi.org\/10.1124\/mol.115.098202","journal-title":"Mol Pharmacol"},{"key":"1923_CR35","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1073\/pnas.0909310107","volume":"107","author":"J Jiang","year":"2010","unstructured":"Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L et al (2010) Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A 107:2307\u20132312. https:\/\/doi.org\/10.1073\/pnas.0909310107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1923_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1021\/acschemneuro.7b00486","volume":"9","author":"J Jiang","year":"2018","unstructured":"Jiang J, Van TM, Ganesh T, Dingledine R (2018) Discovery of 2-piperidinyl phenyl benzamides and trisubstituted pyrimidines as positive allosteric modulators of the prostaglandin receptor EP2. ACS Chem Neurosci 9:699\u2013707. https:\/\/doi.org\/10.1021\/acschemneuro.7b00486","journal-title":"ACS Chem Neurosci"},{"key":"1923_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","volume":"32","author":"RJ Racine","year":"1972","unstructured":"Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281\u2013294. https:\/\/doi.org\/10.1016\/0013-4694(72)90177-0","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"1923_CR38","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1073\/pnas.94.8.4103","volume":"94","author":"PE Schauwecker","year":"1997","unstructured":"Schauwecker PE, Steward O (1997) Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci U S A 94:4103\u20134108. https:\/\/doi.org\/10.1073\/pnas.94.8.4103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1923_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuropharm.2019.02.011","volume":"149","author":"J Jiang","year":"2019","unstructured":"Jiang J, Yu Y, Kinjo ER, Du Y, Nguyen HP, Dingledine R (2019) Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology 149:149\u2013160. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.011","journal-title":"Neuropharmacology"},{"key":"1923_CR40","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3390\/ijms16010758","volume":"16","author":"A Reiner","year":"2014","unstructured":"Reiner A, Heldt SA, Presley CS, Guley NH, Elberger AJ, Deng Y, D'Surney L, Rogers JT et al (2014) Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189. Int J Mol Sci 16:758\u2013787. https:\/\/doi.org\/10.3390\/ijms16010758","journal-title":"Int J Mol Sci"},{"key":"1923_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.exer.2019.03.013","volume":"182","author":"NM Guley","year":"2019","unstructured":"Guley NM, Del Mar NA, Ragsdale T, Li C, Perry AM, Moore BM, Honig MG, Reiner A (2019) Amelioration of visual deficits and visual system pathology after mild TBI with the cannabinoid type-2 receptor inverse agonist SMM-189. Exp Eye Res 182:109\u2013124. https:\/\/doi.org\/10.1016\/j.exer.2019.03.013","journal-title":"Exp Eye Res"},{"issue":"4","key":"1923_CR42","doi-asserted-by":"publisher","first-page":"ENEURO.0387-16.","DOI":"10.1523\/ENEURO.0387-16.2017","volume":"4","author":"Yu Liu","year":"2017","unstructured":"Liu Y, McAfee SS, Guley NM, Del Mar N, Bu W, Heldt SA, Honig MG, Moore BM, 2nd, Reiner A, Heck DH (2017) Abnormalities in dynamic brain activity caused by mild traumatic brain injury are partially rescued by the cannabinoid type-2 receptor inverse agonist SMM-189. eNeuro 4. https:\/\/doi.org\/10.1523\/ENEURO.0387-16.2017","journal-title":"eneuro"},{"key":"1923_CR43","doi-asserted-by":"publisher","first-page":"9459","DOI":"10.1038\/s41598-017-09528-z","volume":"7","author":"X Kang","year":"2017","unstructured":"Kang X, Qiu J, Li Q, Bell KA, Du Y, Jung DW, Lee JY, Hao J et al (2017) Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep 7:9459. https:\/\/doi.org\/10.1038\/s41598-017-09528-z","journal-title":"Sci Rep"},{"key":"1923_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nbd.2014.12.032","volume":"76","author":"J Jiang","year":"2015","unstructured":"Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R (2015) Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis 76:126\u2013136. https:\/\/doi.org\/10.1016\/j.nbd.2014.12.032","journal-title":"Neurobiol Dis"},{"key":"1923_CR45","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/bph.14622","volume":"176","author":"J Qiu","year":"2019","unstructured":"Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, Yu JJ, Yu Y et al (2019) Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. Br J Pharmacol 176:1680\u20131699. https:\/\/doi.org\/10.1111\/bph.14622","journal-title":"Br J Pharmacol"},{"key":"1923_CR46","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1073\/pnas.1120195109","volume":"109","author":"J Jiang","year":"2012","unstructured":"Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, Speigel I, Rojas A et al (2012) Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A 109:3149\u20133154. https:\/\/doi.org\/10.1073\/pnas.1120195109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1923_CR47","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1073\/pnas.1218498110","volume":"110","author":"J Jiang","year":"2013","unstructured":"Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R (2013) Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A 110:3591\u20133596. https:\/\/doi.org\/10.1073\/pnas.1218498110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1923_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nprot.2006.170","volume":"1","author":"RM Deacon","year":"2006","unstructured":"Deacon RM (2006) Assessing nest building in mice. Nat Protoc 1:1117\u20131119. https:\/\/doi.org\/10.1038\/nprot.2006.170","journal-title":"Nat Protoc"},{"key":"1923_CR49","doi-asserted-by":"publisher","unstructured":"Roux S, Sable E, Porsolt RD (2005) Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. Curr Protoc Pharmacol Chapter 10:Unit 10 10. https:\/\/doi.org\/10.1002\/0471141755.ph1010s27","DOI":"10.1002\/0471141755.ph1010s27"},{"key":"1923_CR50","doi-asserted-by":"publisher","first-page":"e00159","DOI":"10.1002\/prp2.159","volume":"3","author":"C Presley","year":"2015","unstructured":"Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM (2015) Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Pharmacol Res Perspect 3:e00159. https:\/\/doi.org\/10.1002\/prp2.159","journal-title":"Pharmacol Res Perspect"},{"key":"1923_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","volume":"36","author":"O Devinsky","year":"2013","unstructured":"Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA (2013) Glia and epilepsy: excitability and inflammation. Trends Neurosci 36:174\u2013184. https:\/\/doi.org\/10.1016\/j.tins.2012.11.008","journal-title":"Trends Neurosci"},{"key":"1923_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1742-2094-11-98","volume":"11","author":"JD Cherry","year":"2014","unstructured":"Cherry JD, Olschowka JA, O'Banion MK (2014) Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11:98. https:\/\/doi.org\/10.1186\/1742-2094-11-98","journal-title":"J Neuroinflammation"},{"key":"1923_CR53","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/cne.24040","volume":"524","author":"CS von Bartheld","year":"2016","unstructured":"von Bartheld CS, Bahney J, Herculano-Houzel S (2016) The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol 524:3865\u20133895. https:\/\/doi.org\/10.1002\/cne.24040","journal-title":"J Comp Neurol"},{"key":"1923_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.brainres.2009.01.036","volume":"1262","author":"KW Falenski","year":"2009","unstructured":"Falenski KW, Carter DS, Harrison AJ, Martin BR, Blair RE, DeLorenzo RJ (2009) Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res 1262:64\u201372. https:\/\/doi.org\/10.1016\/j.brainres.2009.01.036","journal-title":"Brain Res"},{"key":"1923_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eplepsyres.2018.10.002","volume":"148","author":"Q Wu","year":"2018","unstructured":"Wu Q, Wang H (2018) The spatiotemporal expression changes of CB2R in the hippocampus of rats following pilocarpine-induced status epilepticus. Epilepsy Res 148:8\u201316. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.10.002","journal-title":"Epilepsy Res"},{"key":"1923_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13:227\u2013232. https:\/\/doi.org\/10.1038\/nrg3185","journal-title":"Nat Rev Genet"},{"key":"1923_CR57","doi-asserted-by":"publisher","first-page":"24794","DOI":"10.1074\/jbc.271.40.24794","volume":"271","author":"VL Marcheselli","year":"1996","unstructured":"Marcheselli VL, Bazan NG (1996) Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem 271:24794\u201324799. https:\/\/doi.org\/10.1074\/jbc.271.40.24794","journal-title":"J Biol Chem"},{"key":"1923_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/epi.12461","volume":"55","author":"A Rojas","year":"2014","unstructured":"Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R (2014) Cyclooxygenase-2 in epilepsy. Epilepsia 55:17\u201325. https:\/\/doi.org\/10.1111\/epi.12461","journal-title":"Epilepsia"},{"key":"1923_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.tips.2013.05.003","volume":"34","author":"J Jiang","year":"2013","unstructured":"Jiang J, Dingledine R (2013) Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci 34:413\u2013423. https:\/\/doi.org\/10.1016\/j.tips.2013.05.003","journal-title":"Trends Pharmacol Sci"},{"key":"1923_CR60","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/brain\/awx214","volume":"140","author":"JA Hartings","year":"2017","unstructured":"Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, Winkler MKL, Major S et al (2017) Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain 140:2673\u20132690. https:\/\/doi.org\/10.1093\/brain\/awx214","journal-title":"Brain"},{"key":"1923_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trecan.2016.12.002","volume":"3","author":"J Jiang","year":"2017","unstructured":"Jiang J, Qiu J, Li Q, Shi Z (2017) Prostaglandin E2 signaling: alternative target for glioblastoma? Trends Cancer 3:75\u201378. https:\/\/doi.org\/10.1016\/j.trecan.2016.12.002","journal-title":"Trends Cancer"},{"key":"1923_CR62","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drudis.2016.09.017","volume":"22","author":"J Qiu","year":"2017","unstructured":"Qiu J, Shi Z, Jiang J (2017) Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov Today 22:148\u2013156. https:\/\/doi.org\/10.1016\/j.drudis.2016.09.017","journal-title":"Drug Discov Today"},{"key":"1923_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1586\/14737175.2016.1134322","volume":"16","author":"Y Du","year":"2016","unstructured":"Du Y, Kemper T, Qiu J, Jiang J (2016) Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Rev Neurother 16:123\u2013130. https:\/\/doi.org\/10.1586\/14737175.2016.1134322","journal-title":"Expert Rev Neurother"},{"key":"1923_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","volume":"813","author":"R Dingledine","year":"2014","unstructured":"Dingledine R, Varvel NH, Dudek FE (2014) When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol 813:109\u2013122. https:\/\/doi.org\/10.1007\/978-94-017-8914-1_9","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"1923_CR65","doi-asserted-by":"publisher","first-page":"a022772","DOI":"10.1101\/cshperspect.a022772","volume":"5","author":"Pierre-Pascal Lenck-Santini","year":"2015","unstructured":"Lenck-Santini PP, Scott RC (2015) Mechanisms responsible for cognitive impairment in epilepsy. Cold Spring Harb Perspect Med 5. https:\/\/doi.org\/10.1101\/cshperspect.a022772","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"1923_CR66","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.yebeh.2012.11.040","volume":"26","author":"J Chin","year":"2013","unstructured":"Chin J, Scharfman HE (2013) Shared cognitive and behavioral impairments in epilepsy and Alzheimer\u2019s disease and potential underlying mechanisms. Epilepsy Behav 26:343\u2013351. https:\/\/doi.org\/10.1016\/j.yebeh.2012.11.040","journal-title":"Epilepsy Behav"},{"key":"1923_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yebeh.2013.10.004","volume":"31","author":"E Pineda","year":"2014","unstructured":"Pineda E, Jentsch JD, Shin D, Griesbach G, Sankar R, Mazarati A (2014) Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit\/hyperactivity disorder. Epilepsy Behav 31:267\u2013275. https:\/\/doi.org\/10.1016\/j.yebeh.2013.10.004","journal-title":"Epilepsy Behav"},{"key":"1923_CR68","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1056\/NEJMra1407304","volume":"373","author":"D Friedman","year":"2015","unstructured":"Friedman D, Devinsky O (2015) Cannabinoids in the treatment of epilepsy. N Engl J Med 373:1048\u20131058. https:\/\/doi.org\/10.1056\/NEJMra1407304","journal-title":"N Engl J Med"},{"key":"1923_CR69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.bjp.0707584","volume":"153","author":"GA Cabral","year":"2008","unstructured":"Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240\u2013251. https:\/\/doi.org\/10.1038\/sj.bjp.0707584","journal-title":"Br J Pharmacol"},{"issue":"Suppl 3","key":"1923_CR70","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1528-1167.2010.02624.x","volume":"51","author":"Z Magloczky","year":"2010","unstructured":"Magloczky Z, Toth K, Karlocai R, Nagy S, Eross L, Czirjak S, Vajda J, Rasonyi G et al (2010) Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and humans. Epilepsia 51(Suppl 3):115\u2013120. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02624.x","journal-title":"Epilepsia"},{"key":"1923_CR71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pneurobio.2015.05.003","volume":"131","author":"R Franco","year":"2015","unstructured":"Franco R, Fernandez-Suarez D (2015) Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 131:65\u201386. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.05.003","journal-title":"Prog Neurobiol"},{"key":"1923_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbi.2017.08.015","volume":"67","author":"G Navarro","year":"2018","unstructured":"Navarro G, Borroto-Escuela D, Angelats E, Etayo I, Reyes-Resina I, Pulido-Salgado M, Rodriguez-Perez AI, Canela EI et al (2018) Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer\u2019s disease and levodopa-induced dyskinesia. Brain Behav Immun 67:139\u2013151. https:\/\/doi.org\/10.1016\/j.bbi.2017.08.015","journal-title":"Brain Behav Immun"},{"key":"1923_CR73","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.molmed.2019.04.009","volume":"25","author":"B Buisseret","year":"2019","unstructured":"Buisseret B, Alhouayek M, Guillemot-Legris O, Muccioli GG (2019) Endocannabinoid and prostanoid crosstalk in pain. Trends Mol Med 25:882\u2013896. https:\/\/doi.org\/10.1016\/j.molmed.2019.04.009","journal-title":"Trends Mol Med"},{"key":"1923_CR74","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tips.2014.04.006","volume":"35","author":"DJ Hermanson","year":"2014","unstructured":"Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S (2014) Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci 35:358\u2013367. https:\/\/doi.org\/10.1016\/j.tips.2014.04.006","journal-title":"Trends Pharmacol Sci"},{"key":"1923_CR75","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.tips.2014.03.001","volume":"35","author":"M Alhouayek","year":"2014","unstructured":"Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35:284\u2013292. https:\/\/doi.org\/10.1016\/j.tips.2014.03.001","journal-title":"Trends Pharmacol Sci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01923-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-020-01923-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01923-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T01:53:05Z","timestamp":1620265985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-020-01923-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1923"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-01923-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal work was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Tennessee Health Science Center and performed in accordance with the Guide for the Care and Use of Laboratory Animals (the Guide) from the NIH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}